The phase II CCTGCO.26 study (NCT02870920) used PD-L1 monoclonal antibodies in combination with CTLA-4 monoclonal antibodies to treat patients with advanced refractory CRC (98% of whom were pMMR/MSS) [29]. Here, CTLA4 is linked to colorectal carcinoma.